Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588843 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
A Phase 2 study of Colitis, Ulcerative, sponsored by Sanofi.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT05588843: Active Phase 2 study of Colitis, Ulcerative, sponsored by Sanofi.
NCT05588843 is a Phase 2 study of Colitis, Ulcerative that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 187 participants, below the 399-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05588843, a Phase 2 study of Colitis, Ulcerative, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.
Primary Outcome
The Mayo score (full MS) is a composite instrument that consists of patient reported stool frequency and rectal bleeding, endoscopy-derived measures and physician-reported assessment (PGA). The modified Mayo score is calculated omitting PGA. And an endoscopy score of 1 with no friability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAR443122
Study Locations (20)
Texas
- Houston Methodist Hospital- Site Number : 8400023 - Houston
- 1960 Family Practice- Site Number : 8400019 - Houston
- GI Alliance - Mansfield- Site Number : 8400010 - Mansfield
- Integrity Research - Sugar Land- Site Number : 8400026 - Sugar Land
Other
- Investigational Site Number : 0320002 - Buenos Aires
- Investigational Site Number : 0320004 - Córdoba
- Investigational Site Number : 0320005 - Córdoba
New York
- NY Scientific- Site Number : 8400013 - Brooklyn
- Pioneer Clinical Research - New York- Site Number : 8400017 - New York
California
- Om Research - Lancaster - 15th Street West- Site Number : 8400014 - Lancaster
Georgia
- Agile Clinical Research Trials- Site Number : 8400024 - Atlanta
Illinois
- Endeavor Health - Evanston Hospital- Site Number : 8400027 - Evanston
Missouri
- BVL Research- Site Number : 8400015 - Liberty
Nevada
- Vector Clinical Trials- Site Number : 8400004 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2026-12-02 |
| Phase | Phase 2 |
What the registry record for NCT05588843 still lists
NCT05588843 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 399-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05588843 names 20 study sites across 14 states, led by Texas, Other, New York.
Frequently Asked Questions
What is clinical trial NCT05588843 about?
NCT05588843 is a clinical study titled "Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis". This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple ...
What is the current status of trial NCT05588843?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2022-11-25. Estimated completion is 2026-12-02.
What conditions does trial NCT05588843 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT05588843?
The interventions under investigation include: Placebo (DRUG), SAR443122 (DRUG).
Who is sponsoring clinical trial NCT05588843?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588843 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05588843's enrollment target sits among peer trials
187 19th of 28 higher than 10 of 28 other Colitis, Ulcerative trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colitis, Ulcerative trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RECRUITING · Phase 2
-
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI